Coeliac Disease
The purpose of this research study is to assess the effect of 3 different dosages and 2 different dosing schedules of ZED1227 oral capsules in the treatment of Celiac Disease that is symptomatic despite a gluten free diet.
The compound ZED1227 is a newly developed inhibitor of Transglutaminase 2 (TG2). TG2 is a protein found in the small intestine mucosa which is central to the development of coeliac disease. TG2 has a role in activating the immune system (through T-cells) which leads to inflammation and damage of the small intestine mucosa. This study will look at the effects of ZED1227 including changes in the small intestine mucosa (duodenal mucosa) and changes in Coeliac disease symptoms. Other effects studied include changes in inflammation due to Coeliac disease and the safety and tolerability of ZED 1227.